ArticleFrontiers in pharmacology2025
Risk prediction model for severe potential drug-drug interactions in colorectal cancer patients: a real-world data study.
Article in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: The potential drug-drug interactions (pDDIs) seriously affecting the prognosis of colorectal cancer (CRC) patients. This study aimed to identify the risk factors of pDDIs in hospitalized CRC patients and construct a risk prediction model to provide a reference for clinical rational drug use. Research design and methods: A retrospective cohort study was conducted, enrolling 2,868 patients from a tertiary hospital. Medscape was used to assess pDDIs, and a risk prediction model was constructed based on independent risk factors. Results: A total of 1,790 (62.41%) patients experienced at least one pDDIs, with 1,458 (50.84%) cases of severe pDDIs. The number of drug varieties, hypoalbuminemia, and treatment were independent risk factors. The area under the receiver operating characteristic curve (AUC) of the model in the training and validation sets were 0.826 and 0.824, respectively. The calibration curve showed a good agreement between the predicted probability and the actual occurrence probability. Decision curve analysis (DCA) demonstrated that the model had a positive net clinical benefit within a wide range of 10%-90%. Conclusion: The constructed model has good predictive performance and can be used to identify high-risk patients with pDDIs in clinical practice, thereby improving the safety of drug use.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.